Develops oral delivery systems for peptides and proteins, focusing on diabetes and other diseases.
Oramed Pharmaceuticals Inc., based in New York, specializes in pioneering pharmaceutical solutions aimed at advancing diabetes treatment through innovative oral delivery methods. Since its inception in 2002, the company has focused on developing orally ingestible capsules and pills designed to deliver polypeptides effectively. Among its notable products is ORMD-0801 Type 2, an insulin capsule that has successfully completed phase II clinical trials. This groundbreaking treatment is tailored for individuals with diabetes, offering a convenient alternative to traditional insulin administration.
In addition to its diabetes-focused initiatives, Oramed Pharmaceuticals has expanded its portfolio to address non-alcoholic steatohepatitis (NASH), a progressive liver disease. The company's ORMD-0801, currently in phase 2 clinical trials, represents an oral insulin capsule specifically developed for NASH treatment. Furthermore, Oramed is advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule that has completed phase I clinical trials. This formulation aims to provide an effective therapeutic option for managing type 2 diabetes, demonstrating Oramed's commitment to innovation across multiple facets of diabetes care.
Formerly known for its pivotal contributions in diabetes research, Oramed Pharmaceuticals Inc. continues to lead the field with its cutting-edge approach to oral peptide delivery. By leveraging its robust research and development capabilities, Oramed strives to introduce transformative treatments that enhance patient convenience, efficacy, and quality of life in managing diabetes and associated conditions.